See more : Power Grid Corporation of India Limited (POWERGRID.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Ocugen, Inc. (OCGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocugen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Genuine Marketing Group Inc. (GMGZ) Income Statement Analysis – Financial Results
- Tekkorp Digital Acquisition Corp. (TEKK) Income Statement Analysis – Financial Results
- Nextedia S.A. (ALNXT.PA) Income Statement Analysis – Financial Results
- AIB Acquisition Corporation (AIBBR) Income Statement Analysis – Financial Results
- Shanghai Friendess Electronic Technology Corporation Limited (688188.SS) Income Statement Analysis – Financial Results
Ocugen, Inc. (OCGN)
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 2.49M | 0.00 | 42.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 26.00K |
| Cost of Revenue | 704.00K | 1.07M | 589.00K | 6.35K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 1.42M | -589.00K | 36.27K | -60.61K | -49.62K | -1.53M | -1.67M | -1.61M | 0.00 | 8.00K | 26.00K |
| Gross Profit Ratio | 88.34% | 56.87% | 0.00% | 85.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 39.57M | 49.76M | 35.11M | 6.35M | 8.09M | 15.63M | 15.57M | 21.58M | 23.24M | 25.86M | 11.95M | 11.94M |
| General & Administrative | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Other Expenses | 0.00 | 3.52M | -310.00K | 182.66K | -784.87K | 1.43M | -116.00K | -248.00K | -72.00K | 13.00K | -52.00K | -30.00K |
| Operating Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Cost & Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Interest Income | 0.00 | 1.40M | 0.00 | 1.07K | 1.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 79.00K | 720.96K | 1.77M | 163.00K | 134.00K | -60.00K | -133.00K | -151.00K | 0.00 | 798.00K |
| Depreciation & Amortization | 704.00K | 480.00K | 589.00K | 102.11K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 726.00K | 566.00K | 638.00K |
| EBITDA | -64.83M | -88.59M | -58.03M | -21.00M | -18.41M | -14.42M | -24.88M | -11.38M | -30.28M | -21.92M | -16.22M | -14.33M |
| EBITDA Ratio | -1,074.01% | -3,411.09% | 0.00% | -33,085.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -91,800.00% | -50,734.62% |
| Operating Income | -65.53M | -84.87M | -58.03M | -21.28M | -14.16M | -30.11M | -24.95M | -30.31M | -31.82M | -32.66M | -16.85M | -14.97M |
| Operating Income Ratio | -1,085.67% | -3,411.09% | 0.00% | -49,940.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -210,562.50% | -57,569.23% |
| Total Other Income/Expenses | 2.45M | 2.27M | -389.00K | -536.95K | -6.08M | 11.89M | -1.46M | 14.10M | -205.00K | 9.87M | -8.87M | -1.97M |
| Income Before Tax | -63.08M | -81.35M | -58.42M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Income Before Tax Ratio | -1,045.03% | -3,269.73% | 0.00% | -51,201.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| Income Tax Expense | 0.00 | -4.00M | -52.00K | 801.52K | 982.96K | -15.76M | -186.00K | -15.82M | -1.17M | -10.52M | 8.88M | 1.94M |
| Net Income | -63.08M | -77.83M | -58.37M | -22.62M | -21.23M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Net Income Ratio | -1,045.03% | -3,128.38% | 0.00% | -53,081.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| EPS | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -68.21 | -145.22 | -891.47 | -120.93 | -79.65 |
| EPS Diluted | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -67.58 | -145.22 | -891.47 | -120.93 | -79.65 |
| Weighted Avg Shares Out | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.83K | 237.62K | 220.52K | 25.57K | 212.62K | 212.62K |
| Weighted Avg Shares Out (Dil) | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.84K | 239.82K | 220.52K | 25.57K | 212.62K | 212.62K |
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treating retinal diseases, with potential to become a market leader...
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing
3 Penny Stocks Set to Make New Millionaires in 2024
In stock investing, choosing which penny stocks to buy might greatly influence one's future financial situation and wealth. A thorough grasp of companies that exhibit massive growth potential, strategic financial management, and operational efficiency is vital in the present market.
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been...
OCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”),...
OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 10,...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm.
FINAL OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN). Such investors are advised to contact Danielle Peyton at [email protected] or...
Source: https://incomestatements.info
Category: Stock Reports